Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research
Open Access
- 13 February 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (4), 1863
- https://doi.org/10.3390/ijms22041863
Abstract
Cannabidiol (CBD) is the most abundant non-psychoactive component of cannabis; it displays a very low affinity for cannabinoid receptors, facilitates endocannabinoid signaling by inhibiting the hydrolysis of anandamide, and stimulates both transient receptor potential vanilloid 1 and 2 and serotonin type 1A receptors. Since CBD interacts with a wide variety of molecular targets in the brain, its therapeutic potential has been investigated in a number of neuropsychiatric diseases, including anxiety and mood disorders. Specifically, CBD has received growing attention due to its anxiolytic and antidepressant properties. As a consequence, and given its safety profile, CBD is considered a promising new agent in the treatment of anxiety and mood disorders. However, the exact molecular mechanism of action of CBD still remains unknown. In the present preclinical review, we provide a summary of animal-based studies that support the use of CBD as an anxiolytic- and antidepressant-like compound. Next, we describe neuropharmacological evidence that links the molecular pharmacology of CBD to its behavioral effects. Finally, by taking into consideration the effects of CBD on DNA methylation, histone modifications, and microRNAs, we elaborate on the putative role of epigenetic mechanisms in mediating CBD’s therapeutic outcomes.This publication has 110 references indexed in Scilit:
- Microglial Dysregulation in Psychiatric DiseaseJournal of Immunology Research, 2013
- Cannabidiol in Humans—The Quest for Therapeutic TargetsPharmaceuticals, 2012
- H3K4 tri-methylation in synapsin genes leads to different expression patterns in bipolar disorder and major depressionInternational Journal of Neuropsychopharmacology, 2012
- Combinatorial complexity in chromatin structure and function: revisiting the histone codeCurrent Opinion in Genetics & Development, 2012
- Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibitionNeuroscience Letters, 2011
- Antidepressant-like effect of Δ9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.Pharmacology Biochemistry and Behavior, 2010
- Genetic Deletion of Fatty Acid Amide Hydrolase Alters Emotional Behavior and Serotonergic Transmission in the Dorsal Raphe, Prefrontal Cortex, and HippocampusNeuropsychopharmacology, 2010
- Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implicationsBiological Psychiatry, 2008
- The use of the elevated plus maze as an assay of anxiety-related behavior in rodentsNature Protocols, 2007
- Epigenetic programming by maternal behaviorNature Neuroscience, 2004